The US Food and Drug Administration's use of pathologic complete response as regulatory endpoint: Did it pay off?

Jia Luo, Vinay Prasad

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'The US Food and Drug Administration's use of pathologic complete response as regulatory endpoint: Did it pay off?'. Together they form a unique fingerprint.

Medicine & Life Sciences